Biomarkers that tell how the body is doing, and they are measurable. Biomarkers are an integral part of drug research and development processes; they are required, as the tests have to assess the effectiveness of medicines on human beings during clinical investigations.
As per the Biomarkers industry research by Fact.MR - a market research and competitive intelligence provider, historically, from 2017 to 2021, market value of the Biomarkers industry increased at around 13.6% CAGR, wherein, countries such as the Germany, U.S., China and Japan held significant share in the global market.
For More Insights into the Market, Request a Sample of This Report:
https://www.factmr.com/connectus/sample?flag=S&rep_id=7181?SP
Key findings of the Biomarkers market study:
· Regional breakdown of the Biomarkers market based on predefined taxonomy.
· Innovative manufacturing processes implemented by Biomarkers vendors in detail.
· Region-wise and country-wise fragmentation of the Biomarkers market to grasp the revenue, and growth outlook in these areas.
· Changing preferences among consumers across various regions and countries.
· Factors (Positive and Negative) impacting the growth of the global Biomarkers market.
Competitive Landscape:
The key players such as F. Hoffmann-La Roche Ltd.; Abbott Laboratories; Epigenetics AG; Johnson & Johnson Services, Inc.; Thermo Fisher Scientific, Inc. adopt several organic and inorganic strategies to enhance their revenue and market standings.
Some of the recent developments of key Biomarkers providers are as follows :
- In May, 2021, Cerascreen KRAS RGQ PCR Kit, the first FDA-approved diagnostic tissue specimen to identify KRAS G12C mutations in QIAGEN NV NSCLC tumors and expand precision medical options for lung cancer, was launched.
- In April, 2021, F. Hoffmann La Roche Ltd. launched two cardiac biomarker tests, the Sensitive Cardiac Troponin T (cTnThs) and the N-Terminal Pro Brain Sodium Diuretic Peptide Test (NTproBNP). These gold standard biomarkers support the management of cardiovascular disease and may help physicians diagnose heart attacks and better manage heart failure.
- In July 2020, Thermo Fisher Scientific has signed an agreement with Chugai to expand the use of oncomin Dx targeted tests in patients with non-small cell lung cancer (NSCLC) and accelerate local biomarker tests.
- In January 2020, in partnership with the Institute for Microbial Technology (CSIRIMTECH), Merck KGaA opened a research institute in Chandigarh, India, with a focus on genome editing, biomarker detection, and life sciences. The facility is equipped with cutting-edge technology needed for on-site students.
For In-Depth Competitive Analysis, Buy Now:
https://www.factmr.com/checkout/7181?SP
Key Segments Covered in Biomarkers Survey:
- By Disease Type :
- Cardiovascular Diseases
- Cancer
- Neurological Diseases
- Immunological Diseases
- Other Disease Types
- By Type :
- Safety
- Efficacy
- Validation
- By Application :
- Diagnostics
- Drug Discovery & Development
- Personalized Medicines
- Other Applications
- By Region :
- North America
- Latin America
- Europe
- Asia Pacific
- Middle East & Africa
Why choose Fact.MR?
Reports published by Fact.MR are a result of the combination of our experts and digital technologies. We thrive to provide innovative business solutions to the clients as well as tailor the reports aligning with the clients’ requisites. Our analysts perform comprehensive research to offer ins and outs of the current market situation. Clients across various time zones tend to utilize our 24/7 service availability.
Contact:
US Sales Office :
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583
E-Mail: sales@factmr.com